Prenetics Global Limited (PRE)
After hours:
| Previous Close | 4.9700 |
| Open | 4.8600 |
| Bid | 4.5800 x 400 |
| Ask | 4.7300 x 100 |
| Day's Range | 4.6100 - 4.9243 |
| 52 Week Range | 2.8500 - 15.9000 |
| Volume | |
| Avg. Volume | 132,058 |
| Market Cap | 56.266M |
| Beta (5Y Monthly) | -0.11 |
| PE Ratio (TTM) | 1.06 |
| EPS (TTM) | N/A |
| Earnings Date | N/A |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | N/A |
- PR Newswire
Prenetics Announces Fourth Quarter and Full Year 2023 Financial Results
Prenetics Global Limited (NASDAQ: PRE) ("Prenetics" or the "Company"), a leading genomics-driven health sciences company, today announced unaudited financial results for the fourth quarter and full year ended December 31, 2023, along with recent business updates.
- PR Newswire
Prenetics Announces MOU for a Strategic Investment and 5-Year Research Collaboration with Metavisionaries to Pioneer R&D on the International Space Station
Prenetics Global Limited (NASDAQ:PRE), a leading genomics-driven health sciences company, announces the signing of a Memorandum of Understanding (MOU), that paves the way for a strategic investment in Metavisionaries and a pioneering five-year research agreement with them and their partners Space Application Services through their Metaspace Venture. The parties will also establish a Space Innovation Lab within the UAE Space Agency. The inaugural Prenetics research cube is scheduled to on-board t
- PR Newswire
Prenetics Announces Third Quarter 2023 Financial Results
Prenetics Global Limited (NASDAQ: PRE) ("Prenetics" or the "Company"), a leading genomics-driven health sciences company, today announced financial results for the third quarter ended September 30, 2023, along with recent business updates.
